| |
| |
|
| Insider
Information: |
Koppel Adam |
| Relationship: |
10% Owner |
| City: |
Boston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
6,790 |
|
|
Indirect Shares
|
101,509,242 |
|
|
| Direct
Value |
$694,263 |
|
|
|
Indirect Value
|
$2,927,222,886 |
|
|
| Total
Shares |
101,516,032 |
|
|
| Total
Value |
$2,927,917,150 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
6
|
1
|
|
Stock
price went up :
|
4
|
0
|
| Stock
price went down : |
2
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
-1.0
|
| Percentage
Gain/Loss : |
 45.2%
|
 -14.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
PTC Therapeutics, Inc. |
PTCT |
Director |
2013-06-25 |
0 |
2013-06-25 |
2,333,333 |
Premium* |
|
|
Biogen Idec Inc |
BIIB |
EVP, Strategy and Bus.... |
2016-06-06 |
2,402 |
2015-06-02 |
0 |
Premium* |
|
|
Dicerna Pharmaceuticals Inc |
DRNA |
Director |
2021-12-28 |
0 |
2021-12-28 |
0 |
Premium* |
|
|
Marinus Pharmaceuticals Inc |
MRNS |
10% Owner |
2017-12-15 |
0 |
2017-12-19 |
3,977,453 |
Premium* |
|
|
Solid Biosciences Inc |
SLDB |
|
2018-01-25 |
0 |
2024-01-11 |
4,034,582 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
Director, 10% Owner |
2018-06-25 |
0 |
2020-10-26 |
8,891,758 |
Premium* |
|
|
Replimune Group Inc |
REPL |
Director |
2018-07-24 |
0 |
2018-07-24 |
2,838,968 |
Premium* |
|
|
Springworks Therapeutics, Inc. |
SWTX |
10% Owner |
2021-08-10 |
1,106 |
2021-08-10 |
4,831,307 |
Premium* |
|
|
Bcls Acquisition Corp. |
BLSA |
Director, 10% Owner |
2020-10-26 |
0 |
2020-10-26 |
487,500 |
Premium* |
|
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director, 10% Owner |
2023-10-16 |
3,282 |
2023-10-16 |
65,679,781 |
Premium* |
|
|
Rapid Micro Biosystems, Inc. |
RPID |
10% Owner |
2021-07-19 |
0 |
2021-07-19 |
8,434,560 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
49 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APTX |
Aptinyx Inc. |
Director |
– • – |
2018-06-25 |
4 |
B |
$16.00 |
$6,400,000 |
I/I |
400,000 |
2,225,092 |
2.1 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,825,092 |
1,825,092 |
0 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • • |
2020-01-14 |
4 |
B |
$3.00 |
$9,999,999 |
I/I |
3,333,333 |
5,558,425 |
2.25 |
% |
|
| APTX |
Aptinyx Inc. |
Director |
– • • |
2020-10-26 |
4 |
B |
$3.00 |
$9,999,999 |
I/I |
3,333,333 |
8,891,758 |
2.25 |
% |
|
| BLSA |
Bcls Acquisition Corp. |
Director |
– • • |
2020-10-26 |
4 |
A |
$10.00 |
$4,875,000 |
I/I |
487,500 |
487,500 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Chief Strategy Officer |
• • – |
2015-06-02 |
4 |
D |
$387.62 |
$330,252 |
D/D |
(852) |
1,662 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Chief Strategy Officer |
• • – |
2015-06-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,384 |
2,514 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Strategy and Bus. Dev. |
• • – |
2016-02-23 |
4 |
D |
$258.99 |
$25,381 |
D/D |
(98) |
1,865 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Strategy and Bus. Dev. |
• • – |
2016-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
301 |
1,963 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Strategy and Bus. Dev. |
• • – |
2016-04-06 |
4 |
AS |
$275.00 |
$28,050 |
D/D |
(102) |
1,848 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Strategy and Bus. Dev. |
• – – |
2016-06-02 |
4 |
D |
$289.73 |
$154,716 |
D/D |
(534) |
2,957 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Strategy and Bus. Dev. |
• – – |
2016-06-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,643 |
3,491 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Strategy and Bus. Dev. |
• • – |
2016-06-06 |
4 |
AS |
$290.00 |
$160,950 |
D/D |
(555) |
2,402 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2020-10-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
338,120 |
|
% |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • • |
2020-10-27 |
4 |
B |
$10.00 |
$100,000,000 |
I/I |
10,000,000 |
60,300,063 |
2.25 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • • |
2020-10-27 |
4 |
A |
$0.00 |
$0 |
I/I |
49,961,943 |
50,300,063 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • • |
2020-11-09 |
4 |
B |
$10.30 |
$3,422,618 |
I/I |
332,293 |
60,632,356 |
2.25 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • • |
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • • |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • • |
2023-10-16 |
4 |
B |
$22.81 |
$124,999,986 |
I/I |
5,480,052 |
65,679,781 |
2.25 |
% |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • • |
2017-12-18 |
4 |
B |
$7.00 |
$1,995,000 |
I/I |
285,000 |
285,000 |
2.25 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • • |
2017-12-18 |
4 |
A |
$0.00 |
$0 |
I/I |
190,849 |
8,930,237 |
0 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • • |
2017-12-18 |
4 |
OE |
$0.00 |
$0 |
I/I |
8,454,388 |
8,739,388 |
0 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • • |
2019-05-29 |
4 |
S |
$12.50 |
$20,000,000 |
I/I |
(1,600,000) |
7,330,237 |
0 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • – |
2019-12-04 |
4 |
S |
$24.68 |
$37,020,000 |
I/I |
(1,500,000) |
4,080,237 |
0 |
- |
|
49 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
